CA2429059A1 - Dispositifs medicaux enrobes pour la prevention et le traitement de l'affection vasculaire - Google Patents
Dispositifs medicaux enrobes pour la prevention et le traitement de l'affection vasculaire Download PDFInfo
- Publication number
- CA2429059A1 CA2429059A1 CA 2429059 CA2429059A CA2429059A1 CA 2429059 A1 CA2429059 A1 CA 2429059A1 CA 2429059 CA2429059 CA 2429059 CA 2429059 A CA2429059 A CA 2429059A CA 2429059 A1 CA2429059 A1 CA 2429059A1
- Authority
- CA
- Canada
- Prior art keywords
- compounds
- medical device
- intraluminal medical
- prevention
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002265 prevention Effects 0.000 title claims abstract 12
- 208000019553 vascular disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 34
- 238000012377 drug delivery Methods 0.000 claims abstract 12
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract 9
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract 9
- 229960002930 sirolimus Drugs 0.000 claims abstract 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract 4
- 230000001225 therapeutic effect Effects 0.000 claims 12
- 230000003902 lesion Effects 0.000 claims 11
- 208000037803 restenosis Diseases 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 239000011248 coating agent Substances 0.000 claims 6
- 238000000576 coating method Methods 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 4
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 2
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims 2
- 239000000039 congener Substances 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- 230000000144 pharmacologic effect Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 238000002586 coronary angiography Methods 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 231100000057 systemic toxicity Toxicity 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
Un médicament et un dispositif d'administration du médicament peuvent servir à traiter des maladies vasculaires. Un dispositif d'administration local est enrobé de rapamycine ou d'un autre médicament, agent ou composé approprié et est administré intraluminalement pour traiter et prévenir une hyperplasie néointimale survenant à la suite d'une angiographie coronarienne transluminale percutanée. L'administration locale de médicaments ou d'agents permet d'augmenter l'efficacité et de réduire la toxicité générale.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38198602P | 2002-05-20 | 2002-05-20 | |
| US60/381,986 | 2002-05-20 | ||
| US10/431,059 | 2003-05-07 | ||
| US10/431,059 US7419678B2 (en) | 2000-05-12 | 2003-05-07 | Coated medical devices for the prevention and treatment of vascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2429059A1 true CA2429059A1 (fr) | 2003-11-20 |
| CA2429059C CA2429059C (fr) | 2011-10-25 |
Family
ID=29584344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2429059A Expired - Lifetime CA2429059C (fr) | 2002-05-20 | 2003-05-20 | Dispositifs medicaux enrobes pour la prevention et le traitement de l'affection vasculaire |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2429059C (fr) |
-
2003
- 2003-05-20 CA CA2429059A patent/CA2429059C/fr not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2429059C (fr) | 2011-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2408838A1 (fr) | Dispositifs d'administration pour le traitement d'affection vasculaire | |
| MXPA03004512A (es) | Dispositivos medicos revestidos para la prevencion y el tratamiento de enfermedad vascular. | |
| CA2425696C (fr) | Dispositifs medicaux revetus pour le traitement de maladies vasculaires | |
| EP1663339B1 (fr) | Prothese endoluminale comprenant un agent therapeutique | |
| US8541014B2 (en) | Gamma-tocopherol therapy for restenosis prevention | |
| AU2001262957B2 (en) | Drug combinations useful for prevention of restenosis | |
| Cremers et al. | Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter | |
| US5383928A (en) | Stent sheath for local drug delivery | |
| MXPA05005471A (es) | Farmaco antiproliferativo y dispositivo de suministro. | |
| AU2001262957A1 (en) | Drug combinations useful for prevention of restenosis | |
| CA2490170A1 (fr) | Administration vasculaire locale de trichostatine a seule ou en combinaison avec du sirolimus afin de prevenir la restenose a la suite d'une lesion vasculaire | |
| EP1087801A1 (fr) | Inhibiteurs de topoisomerase permettant de prevenir la restenose | |
| JP2005531332A (ja) | 狭窄症又はアテローム性硬化症を防止するホルモンを被覆したステント | |
| CN101543659A (zh) | 单独的普罗布考或与西罗莫司联合的局部血管给药系统 | |
| EP1824532A2 (fr) | Dispositifs medicaux et compositions servant a traiter la restenose | |
| Windecker et al. | Sirolimus eluting stent: a new era in interventional cardiology? | |
| CA2429059A1 (fr) | Dispositifs medicaux enrobes pour la prevention et le traitement de l'affection vasculaire | |
| Baumbach et al. | Local delivery of a low molecular weight heparin following stent implantation in the pig coronary artery | |
| Raja | Drug-eluting stents: is it the beginning of the end for coronary artery bypass surgery? | |
| Raja | Drug-Eluting Stents: The Myth, The Reality. | |
| Kiesz et al. | Local delivery of low molecular weight heparins | |
| Voudris | Drug-Eluting Stents in Coronary Interventions | |
| Gershlick et al. | Local drug delivery from coated stents | |
| Jahnke | Emerging Therapies to Counter Restenosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20230523 |